


Entecavir-¹³C₂, ¹⁵N

Cat. No.:	HY-13623S1
Molecular Formula:	C ₁₀ ¹³ C ₂ H ₁₅ N ₄ ¹⁵ NO ₃
Molecular Weight:	280.26
Target:	Isotope-Labeled Compounds
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Entecavir- ¹³ C ₂ , ¹⁵ N (BMS200475- ¹³ C ₂ , ¹⁵ N; SQ34676- ¹³ C ₂ , ¹⁵ N) is a ¹³ C- and ¹⁵ N-labeled Entecavir (HY-13623). Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of HBV, with an EC ₅₀ of 3.75 nM in HepG2 cell.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-246.
- [2]. Innaimo SF, et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. *Antimicrob Agents Chemother*. 1997 Jul;41(7):1444-9.
- [3]. Rivkin A, et al. A review of entecavir in the treatment of chronic hepatitis B infection. *Curr Med Res Opin*. 2005 Nov;21(11):1845-57.
- [4]. Genovesi EV, et al. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. *Antimicrob Agents Chemother*. 1998 Dec;42(12):3209-18.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA